The pharmaceutical supply chain in the U.S. is complicated. It faces issues like new regulations, trade rules, shortages of raw materials, and rising costs. PwC’s 2025 Digital Trends in Operations Survey shows that 89% of pharma and life sciences leaders expect big changes to supply chains because of trade policy shifts. Supply chains need to be quick and flexible to deal with changes in materials, suppliers, and shipping challenges.
AI agents help by automating tasks like supply chain tracking, buying, and logistics monitoring. More than half (53%) of companies use AI to predict and manage supply problems. AI systems can study large amounts of data from suppliers, shipping routes, and market signals to spot risks before problems happen. This is important because supply chains must respond fast to political and economic changes.
Pharma companies that use AI report better productivity and lower costs. PwC’s research found that 62% of pharma leaders say AI tools help improve operations. AI helps by making demand forecasts more accurate, managing inventories better, and improving buying processes. This means less extra stock and fewer shortages, so production matches real market needs without too much spending.
Good data management is key for AI to work well in pharma supply chains. As more operations rely on AI, high-quality and integrated data is very important. The survey shows many companies face problems with data availability and quality (44%) and with integrating systems (47%). Fixing these issues is needed to get accurate forecasts and real-time updates from AI agents.
Demand forecasting is a main area where AI helps a lot. Old methods have trouble with the ups and downs of pharmaceutical markets, especially with rules that can change suddenly. AI uses advanced algorithms and machine learning to find patterns in past sales, seasonal changes, economic data, and even patient trends.
AI agents can work all the time, updating forecasts as new data comes in. This makes predictions more accurate, cuts waste, and lowers the chance of running out of products. It also helps supply planners get ready for quick demand changes caused by public health issues or seasonal sicknesses.
According to PwC, more companies are using AI for demand sensing and forecasting. They want to make these processes automated with AI agents that work on their own to handle tasks within bigger workflows. This trend, called “agentic AI,” is expected to grow fast through 2026. Using AI in demand forecasting helps pharma reduce manual work, make better supply decisions, and match production to real-time needs.
AI agents are also becoming more common in pharmaceutical manufacturing. Industry 4.0 means using new digital tools like AI, Industrial Internet of Things (IIoT), big data analysis, and robots to update manufacturing.
AI helps cut manufacturing cycle times, use resources better, and improve product quality. When AI is combined with IIoT sensors, it can watch equipment in real time. This helps predict when machines need maintenance and reduces downtime. It also helps cut waste and save energy in manufacturing plants, which supports sustainability goals.
Only 21% of companies use digital twins now—these are virtual models of real machines or systems. But those who do say it works well, with 97% seeing benefits. When AI works with digital twins, companies can simulate production and find bottlenecks before they cause problems.
Pharma companies also use AI agents to run and control machines. This lowers human mistakes and improves accuracy. These changes help meet demands for efficiency, safety, and following rules, without adding extra risks.
As pharma companies use more AI in operations, they need good governance and ethics oversight. Research from Capgemini shows that 67% of companies have AI governing bodies to monitor AI use. About 60% address privacy, bias, and rule following in their AI plans. While only 48% actively work on reducing bias, these governance steps aim to use AI carefully.
Sheetal Chawla, Head of Life Sciences for Capgemini Americas, says that talks are moving from “can we do this?” to “how can we do this safely?” This shows people want to avoid risks from using AI too fast without controls. In supply chain and manufacturing, there are fewer ethical worries, but data privacy and accuracy still need attention.
Central governance helps with ongoing monitoring, reducing risks, human supervision, and following laws. These actions are important as AI takes over more complex workflows.
AI agents are part of bigger workflow automation systems that link different operations. These systems let pharma companies automate whole processes, lower manual work, and increase flexibility.
For example, AI agents can work together to handle demand forecasting, buying, and logistics. When they share data in real time, they can warn supervisors about supply risks or trigger automatic purchases, keeping materials available and deliveries on time.
PwC expects 2026 to be a key year for “agentic AI,” where AI agents run tasks in workflows with human supervisors. Governance will include continuous checks and fixing errors. This balance lets AI handle routine tasks while humans focus on bigger decisions.
AI orchestration layers act like command centers. They bring together AI agents from different sellers and let non-technical users like medical administrators and IT managers control AI workflows easily. This makes it simpler to combine AI tools and keeps governance, security, and performance in check.
Pharma companies gain from AI and workflow automation by:
Even with good results, U.S. pharma companies face challenges in using AI fully. Integration is a big issue, with 47% naming it a top challenge. Old systems and separated data make AI adoption harder. Poor data quality also affects AI accuracy.
Switching to AI workflows needs changes in company culture, staff training, and building digital-ready teams. Companies are investing in skill growth because they know continuous learning is needed for long-term AI success.
Also, traditional ways to measure return on investment (ROI) don’t capture all AI benefits. According to Capgemini, real value is in faster innovation, better teamwork, and improved risk handling, not just in efficiency.
People managing U.S. medical practices and pharma operations need to understand how AI agents help in low-risk operational areas. Using AI in supply chain, demand forecasting, and manufacturing can lower costs, boost productivity, and make operations stronger.
Good attention to data quality, system integration, and governance will decide if AI projects succeed. Clear oversight and putting AI into workflows can help AI agents contribute while keeping rules and stability.
Looking ahead, AI will change workforce roles. As AI takes care of specific tasks, humans will shift to overseeing AI and coming up with new ideas. This means companies must rethink their structure and training programs.
Pharma companies and practices that use AI carefully in these areas are likely to improve efficiency and stay competitive in the changing U.S. health care and life sciences fields.
14% of large enterprises report partial or full deployments of AI agents, and 23% are piloting them, indicating a significant move from pilots to practical use in industries including pharma.
Governance ensures responsible use by addressing ethical concerns, compliance, bias mitigation, and privacy issues, which are rising amidst rapid and sometimes uncontrolled AI agent proliferation across enterprises.
It moved from questioning feasibility (‘Can we do it?’) to focusing on responsible scaling and ethical deployment (‘How can we do it responsibly?’), reflecting maturity in adoption strategies.
AI agents are rapidly advancing in low-risk operational applications such as supply chain management and demand forecasting, which have fewer ethical complexities.
Applications include programming, data analysis, performance optimization, reduced manufacturing time, increased production accuracy, and Industry 4.0 practices to enhance manufacturing efficiency.
AI transforms drug discovery by enabling virtual screening of billions of compounds in hours, speeding hit-to-lead identification with deep learning, and achieving 80-90% time savings in early-stage screening.
Challenges include organizational change management and the need for stakeholders to perceive clear benefits to drive adoption and overcome resistance during transformation.
Because AI fundamentally changes the entire R&D and commercialization process, traditional ROI misses transformative effects such as faster market entry, improved clinical trial adaptability, and predictive analytics integration.
About 19% of organizations in life sciences have adopted multi-agent AI systems, reflecting an emerging trend toward complex agent architectures.
67% have AI governing bodies, 60% address privacy, bias, and compliance concerns actively; however, only 48% actively mitigate bias, highlighting growing but incomplete governance efforts.
Simbo is using AI agents to automate all phone related workflows. Connect now to know more.
Schedule AI Agents Demo Now© Since 2019, Simbo AI.
